Alexion Pharmaceuticals and Dicerna™ Pharmaceuticals have announced that Alexion has exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC™ RNAi molecules.
This expands the companies’ existing research collaboration and license agreement to now encompass four targets within the complement pathway. more